Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders

Current Topics in Medicinal Chemistry

Volumn 15, Issue 2, 2015, Pages 163-169

  Miller, Elżbieta ^a,b   Morel, Agnieszka ^c   Saso, Luciano ^e   Saluk, Joanna ^c,d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b III General Hospital in Lodz   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Central nervous system; Melatonin; Neurodegenerative disorders; Oxidative stress

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MELATONIN; NITRIC OXIDE SYNTHASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; SCAVENGING SYSTEM; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; HUMANS; MELATONIN; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION;

EID: 84926294855     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666141209160556     Document Type: Article

References (80)

1. He, F.; Balling, R. The role of regulatory T cells in neurodegenerative diseases. Wiley. Interdiscip. Rev. Syst. Biol. Med., 2013, 5(2), 153-180.
2. Tewari, A.; Mahendru, V.; Sinha, A.; Bilotta, F. Antioxidants: The new frontier for translational research in cerebroprotection. J. Anaesthesiol. Clin. Pharmacol., 2014, 30(2), 160-171.
3. Nowak, J.Z. Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macular degeneration. Pharmacol. Rep., 2013, 65(2), 288-304.
4. Contestabile, A. Role of nitric oxide in cerebellar development and function: focus on granule neurons. Cerebellum., 2012, 11(1), 50-61.
5. Contestabile, A.; Monti, B.; Polazzi, E. Neuronal-glial interactions define the role of nitric oxide in neural functional processes. Curr. Neuropharmacol., 2012, 10(4), 303-310.
6. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87(1), 315-424.
7. Singh, R.P.; Sharad, S.; Kapur, S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. JIACM., 2004, 5(3), 218-225
8. Zhang, Z.; Yan, J.; Chang, Y.; Yan, S.S.; Shi, H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr. Med. Chem., 2011, 18(28), 4335-4343.
9. Trachootham, D.; Lu, W.; Ogasawara, M.A.; Nilsa, R.D.; Huang, P. Redox regulation of cell survival. Antioxid. Redox. Signal., 2008, 10(8), 1343-1374.
10. Nair, A.; Frederick, T.J.; Miller, S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life. Sci., 2008, 65(17), 2702-2720.
11. Gimsa, U.; Mitchison, N.A.; Brunner-Weinzierl, M.C. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm., 2013, 2013, 320-519.
12. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta., 2009, 1788(4), 842-857.
13. Ge, M.; Chi, X.; Zhang, A.; Luo, G.; Sun, G.; Xie, H.; Hei, Z. Intestinal NF-E2-related factor2 expression and antioxidant activity changes in rats undergoing orthotopic liver autotransplantation. Oncol. Lett., 2013, 6(5), 1307-1312.
14. Miller, E.; Multiple sclerosis. Adv. Exp. Med. Biol., 2012, 24, 228-238.
15. Kvietys, P.R.; Granger, D.N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic. Biol. Med., 2012; 52(3), 556-592.
16. Calabrese, V.; Scapagnini, G.; Giuffrida Stella, A.M.; Bates, T.E.; Clark, J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res., 2001, 26(6), 739-764.
17. Camello-Almaraz, C.; Gomez-Pinilla, P.J.; Pozo, M.J.; Camello, P.J. Age-related alterations in Ca2+signals and mitochondrial membrane potential in exocrine cells are prevented by melatonin. J. Pineal. Res., 2008, 45, 191-198.
18. Miller, E.; Wachowicz, B.; Majsterek, I.; Advances in antioxidative therapy of multiple sclerosis. Curr. Med. Chem., 2013,20(37),4720-30.
19. Alexi, T.; Borlongan, C. V.; Faull, R. L. M.; Williams, C. E.; Clark, R. G.; Gluckman, P. D.; Hughes, P.E. Neroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s disease. Prog. Neurobiol., 2000, 60(5), 409-470.
20. Saxena, S.; Caroni, P. Selective Neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron., 2011, 71(1), 35-48.
21. Mills, E.; Dong, X.P.; Wang, F.; Xu, H. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med., Chem., 2010, 2(1), 51-64.
22. Zheng, W.; Monnot, A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol. Ther., 2012, 133(2), 177-188.
23. Slominski, R.M; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol. Cell Endocrinol., 2012, 351(2), 152-166.
24. Tan, D.X.; Manchester, L.C.; Sanchez-Barcelo, E.; Mediavilla, M.D.; Reiter, R.J. Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system. Curr. Neuropharmacol., 2010, 8(3), 162-167.
25. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med., 2009, 15(1-2), 43-50.
26. Wang, X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther., 2009, 15(4), 345-357.
27. Esposito, E.; Cuzzocrea, S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol., 2010, 8(3), 228-242.
28. Das, A.; Belagodu, A.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J. Pineal. Res., 2008, 45(2), 117-124.
29. Alonso-Alconada, D.; Alvarez, A.; Lacalle, J.; Hilario, E. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol. Histopathol., 2012, 27(6), 771-783.
30. Espino, J.; Pariente, J.A.; Rodriguez, A.B. Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid. Med. Cell Longev., 2012; 2012: 670294.
31. Poeggeler, B.; Saarela, S.; Reiter, R.J.; Tan, D.X.; Chen, L.D.; Manchester, L.C.; Barlow-Walden, L.R. Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann. N. Y. Acad. Sci., 1994, 17(738), 419-420.
32. Tan, D.X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Allegra, M.; Hardeland, R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem., 2002, 2(2), 181-197.
33. Hardeland, R.: Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog. Neurobiol., 2011, 93(3), 350-384.
34. Cardinali, D.P.; Pagano, E.S.; Scacchi Bernasconi, P.A.; Reynoso, R.; Scacchi, P. Melatonin and mitochondrial dysfunction in the central nervous system. Horm. Behav., 2013, 63(2), 322-330.
35. Costa, E.J.; Lopes, R.H.; Lamy-Freund, M.T. Permeability of pure lipid bilayers to melatonin. J. Pineal. Res.,1995, 19(3), 123-126.
36. Gupta, Y.K.; Gupta, M.; Kohli, K. Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian. J. Physiol. Pharmacol., 2003, 47(4), 373-386.
37. Luchetti, F.; Canonico, B.; Betti, M.; Arcangeletti, M.; Pilolli, F.; Piroddi, M.; Canesi, L.; Papa, S.; Galli, F. Melatonin signaling and cell protection function. FASEB J., 2010, 24(10), 3603-3624.
38. Escames, G.; Lopez, A.; Garcia, J.A.; Garcia, L.; Acuna-Castroviejo, D.; Garcia, J.J.; Lopez, L.C. The role of mitochondria in brain aging and the effects of melatonin. Curr. Neuropharmacol., 2010, 8(3), 182-193.
39. Dabbeni-Sala, F.; Di Santo, S.; Franceschini, D.; Skaper, S. D.; Giusti, P. Melatonin protects against 6-OHD a induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J., 2001, 15, 164-170.
40. Martin, M.; Macias, M.; Escames, G.; Reiter, R.J.; Agapito, M.T.; Ortiz, G.G.; Acuna-Castroviejo, D. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J. Pineal Res., 2000, 28(4), 242-248.
41. Shamir, E.; Barak, Y.; Shalman, I.; Laudon, M.; Zisapel, N.; Tarrasch, R.; Elizur, A.; Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo controlled, crossover study. Arch. Gen. Psychiatry., 2001, 58(11), 1049-1052.
42. Trivedi, A.K.; Kumar, V. Melatonin: an internal signal for daily and seasonal timing. Indian. J. Exp. Biol., 2014, 52(5), 425-437.
43. Gulcin, I.; Buyukokuroglu, M.E.; Oktay, M.; Kufrevioglu, O.I. On the in vitro antioxidative properties of melatonin. J. Pineal. Res., 2002, 33(3), 167-171.
44. Shokrzadeh, M.; Naghshvar, F.; Ahmadi, A.; Chabra, A.; Jeivad, F.; The potential ameliorative effects of melatonin against cyclophosphamide-induced DNA damage in murine bone marrow cells. Eur Rev Med Pharmacol Sci., 2014, 18(5),605-11.
45. Bonnefont-Rousselot, D.; Collin, F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology., 2010, 278(1), 55-67.
46. Vladan, B.; Panfoli, I. Melatonin and Abeta, Macular Degeneration and Alzheimers Disease: Same Disease, Different Outcomes?. Med. Hypothesis. Discov. Innov. Ophthalmol., 2012, 1(2), 24-32.
47. Zhou, J.; Zhang, S.; Zhao, X.; Wei, T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J. Pineal. Res., 2008, 45(2), 157-165.
48. Butterfield, D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic. Res., 2002, 36(12), 1307-1313.
49. Olcese, J. M.; Cao, C. ; Mori, T. ; Mamcarz, M. B.; Maxwell, A.; Runfeldt, M. J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; Arendash, G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal. Res., 2009, 47(1), 82-96.
50. Vanderstichele, H.; Bibl, M.; Engelborghs, S.; Le Bastard, N.; Lewczuk, P.; Molinuevo, J.L.; Parnetti, L.; Perret-Liaudet, A.; Shaw, L.M.; Teunissen, C.; Wouters, D.; Blennow, K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s biomarkers standardization initiative. Alzheimers Dement., 2012, 8(1), 65-73.
51. Polimeni, G.; Esposito, E.; Bevelacqua, V.; Guarneri, C.; Cuzzocrea, S. Role of melatonin supplementation in neurodegenerative disorders. Front. Biosci., 2014, 19, 429-446.
52. Wollen, K.A. Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with adiscussion of treatment strategies from the perspective of patients and practitioners. Altern. Med. Rev., 2010, 15(3), 223-244.
53. He, H.; Dong, W.; Huang, F. Anti-amyloidogenic and anti apoptotic role of melatonin in Alzheimer disease. Curr. Neuropharmacol., 2010, 8(3), 211-217.
54. Contestabile, A. Oxidative stress in neurodegeneration: mechanisms and therapeutic perspectives. Curr. Top. Med. Chem., 2001, 1(6), 553-568.
55. Honce, J.M. Gray matter pathology in MS: neuroimaging and clinical correlations. Mult. Scler. Int., 2013, 2013, 627870.
56. Daams, M.; Geurts, J.J.; Barkhof, F. Cortical imaging in multiple sclerosis: recent findings and ‘grand challenges’. Curr. Opin. Neurol., 2013, 26(4), 345-352.
57. Davies, A.L.; Desai, R.A.; Bloomfield, P.S.; Macintosh, P.R.; Chapple, K.J.; Linington, C.; Fairless, R.; Diem, R.; Kasti, M.; Murphy, M.P.; Smith, K.J. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann. Neurol., 2013, 74(6), 815-825.
58. Farhadi, N.; Oryan, S.; Nabiuni, M.; Serum level of Melatonin and Cytokines in Multiple Sclerosis Biomed. J., 2014, 37,90-92.
59. Triste, G.; Trapp, B.; Dutta, R. Axonal loss in multiple sclerosis: causes and mechanisms. Handb. Clin. Neurol., 2014, 122, 101-113.
60. Miller, E.; Mrowicka, M.; Malinowska, K.; Kędziora, J.; Majsterek, I. Effects of whole body cryotherapy on oxidative stress in multiple sclerosis patients. J. Therm. Biol., 2010, 35: 406-410.
61. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple scleroisis. Clin Biochem., 2012 Jan; 45(1-2):26-30.
62. Natarajan, R.; Einarsdottir, E.; Riutta, A.; Hagman, S.; Raunio, M.; Mononen, N.; Lehtimaki, T.; Elovaara, I. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. J. Neuroimmunol., 2012, 15, 250(1-2), 106-110.
63. Kashani, I.R.; Rajabi, Z.; Akbari, M.; Hassanzadeh, G.; Mohseni, A.; Eramsadati, M.K.; Rafiee, K.; Beyer, C.; Kipp, M.; Zendedel, A. Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis., (ahead of print). Exp. Brain Res., 2014 Sep;232(9):2835-46
64. Bahamonde, C.; Conde, C.; Aguera, E.; Lillo, R.; Luque, E.; Gascon, F.; Feijoo, M.; Cruz, A.H.; Sanchez-Lopez, F.; Tunez, I. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress. Eur. J. Pharmacol., 2014, 730, 26-30.
65. Melamud, L.; Golan, D.; Luboshitzky, R.; Lavi, I.; Miller, A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J. Neurol. Sci., 2012, 314(1-2), 37-40.
66. Miller, E.; Walczak, A.; Majsterek, I.; Kędziora, J. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J. Neuroimmunol., 2013,15;257(1-2),97-101.
67. Alexander, G.E. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues. Clin. Neurosci., 2004, 6(3), 259-80.
68. Daneault, J.F.; Carignan, B.; Sadikot, A.F.; Panisset, M.; Duval, C. Drug-induced dyskinesia in Parkinson’s disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?. BMC Med., 2013, 11, 76.
69. Iranzo, A.; Gelpi, E.; Tolosa, E.; Molinuevo, J.L.; Serradell, M.; Gaig, C.; Santamaria, J. Neuropathology of prodromal Lewy body disease. Mov. Disord., 2014, 29(3), 410-415.
70. Del Tredici, K.; Braak, H. Dysfunction of the locus coeruleusnorepinephrine system and related circuitry in Parkinson’s diseaserelated dementia. J. Neurol. Neurosurg. Psychiatry., 2013, 84(7), 774-783.
71. Garcia-Garcia, A.; Zavala-Flores, L.; Rodriguez-Rocha, H.; Franco R. Thiol-redox signaling, dopaminergic cell death, and Parkinson’s disease. Antioxid. Redox. Signal., 2012, 17(12), 1764-1784.
72. Adi, N.; Mash, D.C.; Ali, Y.; Singer, C.; Shehadeh, L.; Papapetropoulos, S.; (2010) Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monit., 2010,16,BR61/BR67.
73. Khaldy, H.; Escames, G.; Leon, J.; Vives, F.; Luna, J.D.; Acuna-Castroviejo, D. Comparative effects of melatonin, L deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J. Pineal. Res., 2000, 29(2),100-107.
74. Van der Schyf, C.J.; Castagnoli, K.; Palmer, S.; Hazelwood, L.; Castagnoli, N. Jr. Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox. Res., 2000, 1(4), 261-269.
75. Medeiros, C.A.; Carvalhedo de Bruin, P.F.; Lopes, L.A.; Magalhaes, M.C.; de Lourdes Seabra, M.; deBruin, V.M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J. Neurol., 2007, 254(4), 459-464.
76. Das, A.; Wallace, G.; Reither, RJ.; Varma, AK.; Ray, SK.; Banik, NL.; Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms. J. Pineal. Res., 2013,54,58-68.
77. Weishaupt, J.H.; Bartels, C.; Polking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Huther, G.; Schneider, A.; Bach, A.; Siren, A.L.; Hardeland, R.; Bahr, M.; Nave, K.A.; Ehrenreich, H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal. Res., 2006, 41(4), 313-323.
78. Zhang Y, Cook A, Kim J, Baranov SV, Jiang J, Smith K, Cormier K, Bennett E, Browser RP, Day AL, Carlisle DL, Ferrante RJ, Wang X, Friedlander RM. Melatoin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amylotophic lateral sclerosis. Neurobiol Dis. 2013,55,26-35.
79. Liu, G.; Alpaga, L.; Cai, H. α-synuclein, LRRK2 and their interplay in Parkinson’s disease. Future. Neurol., 2012, 7(2), 145-153.
80. Srinivasan, V.; Lauterbach, E.C.; Ahmed, A.H.; Prasad, A. Alzheimer’s Disease: Focus on the Neuroprotective Role of Melatonin. J. Neurol. Res., 2012, 2(3), 69-81.